Delivery Order SPE2DX22D0010-SPE2D826FCE21
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for Oxymorphone HCL ER Tablets 15mg, with a ceiling value of $1,404.26 and an ultimate completion date of August 25, 2025. This non-competitive, firm fixed-price delivery order represents a pharmaceutical procurement under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $1 billion...
- AmerisourceBergen Drug Corp was awarded a delivery order on October 22, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply Oxymorphone HCL ER Tablets 20mg with a ceiling value of $5,773.98. This is a firm fixed-price delivery order with an ultimate completion date of October 23, 2025, and represents a non-competitive set-aside award. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on November 14, 2025, for the supply of Oxymorphone HCL ER Tablets 20mg, with a contract ceiling value of $3,394.93 and an ultimate completion date of November 17, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the prime contractor, which maintains its corporate office in Conshohocken, Pennsylvania—the designated place of performance....
- On September 25, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $8,331.03 to AmerisourceBergen Drug Corp for the supply of Oxymorphone HCL ER Tablets 10mg. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award to this established pharmaceutical distributor. Performance of this order is scheduled for completion by September 26, 2025, at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency's Medical Supply Chain awarded a $6,172.64 delivery order to AmerisourceBergen Drug Corp for Oxymorphone HCL ER Tablets 20mg, with a completion date of December 31, 2025. This contract represents a non-competitive, firm fixed-price delivery order issued against AmerisourceBergen's existing indefinite delivery contract vehicle. The order will be fulfilled from the vendor's operations in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for Oxymorphone HCL ER Tablets 20mg, valued at $11,664.15 under a firm fixed-price contract type. This non-competitive delivery order represents a single-item pharmaceutical procurement with an ultimate completion date of August 21, 2025. The award was made without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $6,280.65 to AmerisourceBergen Drug Corp for the supply of Oxymorphone HCL ER Tablets 20mg, with an ultimate completion date of December 19, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Oxymorphone HCL ER Tablets 20mg, valued at $11,133.62. This firm fixed-price delivery order, with an ultimate completion date of November 4, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement, reflecting AmerisourceBergen's continued capability...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on December 23, 2025, for the supply of Oxymorphone HCL Extended Release tablets, 15mg. This firm fixed-price delivery order, valued at $1,864.16, represents a child contract under a larger indefinite delivery vehicle and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation and is...
- This delivery order, awarded on August 13, 2025, by the Defense Logistics Agency's Medical Supply Chain to AmerisourceBergen Drug Corp, provides Oxymorphone HCL ER Tablets 40mg with a ceiling value of $2,062.57. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 14, 2025, and carries no set-aside designation, indicating it was competitively awarded. This delivery order is a child contract under AmerisourceBergen Drug Corp's larger...
- SPE2DX22D0010Indefinite Delivery Contract
- SPE2DX22D0010-SPE2D826FCE21Delivery Order
The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Oxymorphone HCL ER Tablets 10mg, with a ceiling value of $7,897.52. This non-competitive delivery order, which is firm fixed price in nature, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The order is scheduled for completion by January 6, 2026, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran healthcare systems through its comprehensive portfolio of brand-name and generic medications, vaccines, and medical supplies. As the prime contractor on this delivery order, the company leverages its DLA Troop Support Medical IDC to supply pharmaceutical products supporting Defense Health Agency requirements and other federal healthcare systems. The company's track record of consistent, competitively awarded contracts across multiple therapeutic domains demonstrates its capability to meet federal procurement standards for critical medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 1/4/26 |